Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...
Auteurs principaux: | López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
MDPI
2019
|
Documents similaires
-
Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
par: César López-Camacho, et autres
Publié: (2019-11-01) -
Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
par: Moorthy, V, et autres
Publié: (2003) -
New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
par: Alharbi, N
Publié: (2014) -
Clinical development of Modified Vaccinia virus Ankara vaccines.
par: Gilbert, S
Publié: (2013) -
Clinical development of Modified Vaccinia virus Ankara vaccines
par: Gilbert, S
Publié: (2013)